A comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent.
Sixty-eight patients with inoperable but 'limited' stage small-cell carcinoma of the bronchus were treated with two different chemotherapy regimens. Thirty-four patients received methotrexate, cyclophosphamide, procarbazine and vincristine in standard dose over a 2-year schedule. Thirty-four patients received cyclophosphamide alone over a period of 3 months. The groups were evenly balanced with respect to clinical details which are fully described. Toxicity was acceptable. The median actual survival for the whole group was 11 months, the 1-year, 2-year and 4-year survival being 48%, 30% and 1.5% respectively. There was no statistically significant difference in survival between those classified as responders and those as non-responders, nor between the groups treated with the two different regimens. There was a high local recurrence rate.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000401:mortality; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D008727:Methotrexate